London, United Kingdom-based fertility tech startup making clinical-grade fertility care available at home, Béa Fertility, raised EUR 2.9 million in funding. The round took place on July 31, 2023. Octopus Ventures led the financing for the firm. Meanwhile, JamJar and Forward Partners joined in the fundraise. Besides, existing investors Calm/Storm and Q Ventures also participated in the financing.
The funds raised so far by the company now amount to EUR 3.8 million.
Purpose of financing for Béa Fertility
With the latest financing, the company seeks to roll out the first Béa Treatment Kits to the public. The first Béa treatment is available to purchase online via Béa’s website now. The first users to purchase a kit will pay just GBP 350 for three ICI treatment cycles, with one Treatment Kit delivered at the beginning of each menstrual cycle throughout the three-month treatment program. The program targets users who are currently trying to conceive.
What the company’s official has to add
Tess Cosad, CEO and co-founder at Béa Fertility said, “Fertility impacts 1 in 6 couples, yet access to fertility care is severely lacking globally. Fertility clinics have been selling the same expensive treatments for decades, yet there are a number of groups which remain underserved, including the LGBTQIA+ community, single people and parents experiencing secondary infertility. At Béa, our aim is to fill this gap by creating inclusive, clinical-grade fertility treatments that can be used at home. This latest injection of funding – from experienced investors with a proven track record of backing successful fertility and femtech businesses – will enable us to get our pioneering treatment in the hands of the people who need it most. We can’t wait for people to try it.”
What the investors have to comment
Kirsten Connell, Investor at Octopus Ventures, further said, “At Octopus Ventures, we back founders who are changing the world for the better. We invest where we can make the greatest positive impact. When it comes to starting a family, there are few things in life more meaningful than this. Béa Fertility, which is reimagining the fertility care pathway, was a clear vision we wanted to get behind. We’re delighted to have joined Tess and her team on this journey.”
In addition, Brian Hatton, Partner at Q Ventures, said, “We backed Tess and the Béa team at the idea stage in their 2021 pre-seed round, and they have made incredible progress since. Their at-home product is truly a groundbreaking new step in the fertility care pathway, and we are excited to continue to support this incredible group as they launch and scale.”
About the company
Tess Cosad and George Thomas launched the company in 2020. The company’s treatment kit enables users to carry out a simple fertility treatment called Intracervical Insemination (ICI) safely at home.
Béa’s aim is to make a transformative and inclusive new fertility offering available to people who are struggling to conceive. It seeks to focus on widening access to care for LGBTQ families as well as groups traditionally excluded from existing fertility provisions.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
